BNTC earnings: next report 2026-09-28, real EPS beat/miss history, analyst consensus Buy, P/E -10.31. Updated 2026-07-23.
Benitec Biopharma (BNTC) Research Hub
Benitec Biopharma (BNTC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.19 USD (-2.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.31, market cap 0.30B. This hub links to the full technical, earnings and options research available for BNTC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.19 USD (-2.09%) |
| 52-week range | 10.86 USD – 13.98 USD |
| Trend regime | Range |
| 14-day RSI | 32.5 (Bearish) |
| Trailing P/E | -10.31 |
| Market cap | 0.30B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-28 |
Available research for BNTC
Covered Call on BNTC: how it works, illustrative setup around the real 12.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BNTC: how it works, illustrative setup around the real 12.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BNTC: how it works, illustrative setup around the real 12.19 USD price, max profit/loss, breakeven and when to use it. Educational.
BNTC technical analysis: range, last 12.19 USD, RSI 32.5, 52w range 10.86 USD–13.98 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BNTC in?
Benitec Biopharma (BNTC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BNTC in an uptrend or downtrend?
As of 2026-09-11, BNTC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BNTC's trailing P/E ratio?
BNTC's trailing P/E is -10.31, with a market cap of 0.30B. See the earnings research page for full valuation detail.
When does BNTC next report earnings?
BNTC is next scheduled to report earnings on 2026-09-28, with a consensus EPS estimate of -0.25 USD.